CN115873596B - Luminescent carbon nanomaterial and application thereof in bone-derived alkaline phosphatase detection - Google Patents
Luminescent carbon nanomaterial and application thereof in bone-derived alkaline phosphatase detection Download PDFInfo
- Publication number
- CN115873596B CN115873596B CN202211406375.9A CN202211406375A CN115873596B CN 115873596 B CN115873596 B CN 115873596B CN 202211406375 A CN202211406375 A CN 202211406375A CN 115873596 B CN115873596 B CN 115873596B
- Authority
- CN
- China
- Prior art keywords
- drs
- pcs
- immunosensor
- electrochemiluminescence
- agnps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 30
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 18
- 102000002260 Alkaline Phosphatase Human genes 0.000 title claims abstract description 16
- 108020004774 Alkaline Phosphatase Proteins 0.000 title claims abstract description 16
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 16
- 238000001514 detection method Methods 0.000 title claims description 20
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims abstract description 56
- 230000000171 quenching effect Effects 0.000 claims abstract description 23
- 239000000523 sample Substances 0.000 claims abstract description 20
- 238000010791 quenching Methods 0.000 claims abstract description 19
- 238000004020 luminiscence type Methods 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 16
- 239000002077 nanosphere Substances 0.000 claims abstract description 13
- CLQUXJZJDVHHMG-UHFFFAOYSA-N nickel;phenol Chemical compound [Ni].OC1=CC=CC=C1.OC1=CC=CC=C1 CLQUXJZJDVHHMG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000002776 aggregation Effects 0.000 claims abstract description 11
- 238000004220 aggregation Methods 0.000 claims abstract description 11
- GEIAQOFPUVMAGM-UHFFFAOYSA-N Oxozirconium Chemical class [Zr]=O GEIAQOFPUVMAGM-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000004048 modification Effects 0.000 claims abstract description 9
- 238000012986 modification Methods 0.000 claims abstract description 9
- 229920002521 macromolecule Polymers 0.000 claims abstract description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 45
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- 229920001661 Chitosan Polymers 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000008055 phosphate buffer solution Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 229910052697 platinum Inorganic materials 0.000 claims description 8
- 238000004729 solvothermal method Methods 0.000 claims description 8
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- -1 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 3
- 238000002484 cyclic voltammetry Methods 0.000 claims description 3
- 229910021397 glassy carbon Inorganic materials 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 229910052726 zirconium Inorganic materials 0.000 claims description 3
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002981 blocking agent Substances 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 238000001000 micrograph Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000007547 Laminin Human genes 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000027756 respiratory electron transport chain Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- 101710134784 Agnoprotein Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011263 electroactive material Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000010335 hydrothermal treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
The invention discloses a luminescent carbon nanomaterial, which is prepared by the following steps: preparing nitrogen-doped carbon dots; and carrying out coordination aggregation on the prepared nitrogen-doped carbon dots and zirconium oxygen clusters to obtain zirconium-coordinated carbon dot dendritic macromolecules (Zr-CD DRs), namely the luminescent carbon nanomaterial. The electrochemiluminescence efficiency of the luminescent carbon nanomaterial is higher than that of the nitrogen-doped carbon dots. The invention also discloses an electrochemiluminescence immunosensor, which comprises an immunosensor containing Zr-CD DRs and a probe containing nickel-phenol coordination nanospheres (Ni-PCS); the Zr-CD DRs are electrochemical luminescence signal labels and electrode modification materials, and the Ni-PCS is a signal quenching material. The electrochemiluminescence immunosensor has excellent sensitivity, specificity, stability and clinical practicability when detecting bone-derived alkaline phosphatase.
Description
Technical Field
The invention relates to a luminescent carbon nanomaterial and application thereof in bone source alkaline phosphatase detection, belonging to the field of electrochemical luminescence sensors.
Background
Bone-derived alkaline phosphatase (BALP) is secreted by osteoblasts, and mainly reflects the activity and function of osteoblasts, and is an important index of bone formation. Currently, the main methods of BALP detection rely on enzyme-linked immunosorbent assay (ELISA) and colorimetric methods. However, the conventional method for detecting BALP by immunological recognition has the problems of poor sensitivity, complex operation, harsh reaction conditions and the like. Therefore, there is a great need to develop simple, enzyme-free and sensitive BALP detection techniques.
Electrochemical luminescence (ECL) immunoassays are widely used because of their high sensitivity, low background, and good specificity. Carbon Dots (CDs) are used as an emerging luminescent carbon nanomaterial, and have the outstanding advantages of low cost, good biocompatibility, easiness in preparation and the like. It was found that the luminescence properties of CDs are largely dependent on their ultra-small size and surface functionality. Therefore, an increase in CDs size significantly reduces the luminous efficiency. In addition, conventional enrichment and immobilization strategies such as electrostatic adsorption and covalent crosslinking may increase the particle size of CDs due to aggregation in practical expansion applications of CDs, resulting in aggregation-induced luminescence quenching effects. In view of this property, it is critical to enrich CDs and maintain a suitable distance to preserve high luminous efficiency of CDs, and thus organic polymer encapsulation can be utilized to enrich CDs. However, organic polymers hinder interactions between CDs and coreactants, thereby reducing ECL performance, which limits their further use in ECL bioassays. Thus, the above-described methods cannot maintain or even increase ECL efficiency while enriching and immobilizing CDs.
Disclosure of Invention
The invention provides a luminescent carbon nanomaterial which can be used for holding or improving ECL efficiency while immobilizing CDs.
In order to achieve the purpose, the technical scheme adopted by the invention is that the luminescent carbon nanomaterial is prepared by the following method: preparing nitrogen-doped carbon dots; and carrying out coordination aggregation on the prepared nitrogen-doped carbon dots and zirconium oxygen clusters to obtain zirconium-coordinated carbon dot dendritic macromolecules (Zr-CD DRs), namely the luminescent carbon nanomaterial.
Further, the nitrogen-doped carbon dots are synthesized by taking citric acid and hydrazine hydrate as raw materials and adopting a solvothermal method.
Further, the solvothermal method for synthesizing the nitrogen-doped carbon dot specifically comprises the following steps: dissolving citric acid in Dimethylformamide (DMF), and then adding hydrazine hydrate dropwise to the DMF solution under stirring to form a mixture; transferring the mixture into a high-pressure reaction kettle with polytetrafluoroethylene lining for solvothermal reaction, cooling to room temperature after the reaction is completed, and centrifuging to obtain an upper solution.
Further, the coordination aggregation of the nitrogen-doped carbon dots and the zirconium oxygen clusters specifically comprises the following steps: zrOCl 2 ·8H 2 O is dissolved in DMF containing nitrogen-doped carbon dots, and is obtained by heating and cooling to room temperature and then separating.
The invention also provides an electrochemiluminescence immunosensor, which comprises an immunosensor containing Zr-CD DRs and a probe containing nickel-phenol coordination nanospheres (Ni-PCS); the Zr-CD DRs are electrochemical luminescence signal labels and electrode modification materials, and the Ni-PCS is a signal quenching material.
Further, the immunosensor containing Zr-CD DRs is a BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor, and is prepared by the following steps: s1, dispersing Zr-CD DRs in a chitosan solution, and then dropwise adding the dispersed Zr-CD DRs onto the surface of a pretreated glassy carbon electrode to obtain a Zr-CD DRs/CS modified electrode; s2, silver nano particles (AgNPs) solution is dripped on the surface of the Zr-CD DRs/CS modified electrode, and the AgNPs/Zr-CD DRs/CS modified electrode is obtained; s3, dripping the BALP antibody (Ab 1) to the surface of the AgNPs/Zr-CD DRs/CS modified electrode obtained in the step S2 to obtain an Ab1/AgNPs/Zr-CD DRs/CS modified electrode; s4, dropwise adding a blocking agent BSA solution to the surface of the electrode modified by the Ab1/AgNPs/Zr-CD DRs/CS obtained in the step S3 to obtain the BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor.
Further, the probe of the nickel-containing phenol coordination nanosphere (Ni-PCS) is an Ab2-Pt@Ni-PCS quenching probe, and the Ab2-Pt@Ni-PCS quenching probe is prepared by the following steps: synthesizing Ni-PCS by formaldehyde auxiliary metal ligand crosslinking method; dispersing the Ni-PCS solution in deionized water containing polyvinylpyrrolidone (PVP), mixing, adding H 2 PtCl 6 Slightly stirring and then adding a reducing agent NaBH 4 The reaction and separation are carried out to obtain the platinum nano particle functionalized nickelPhenol coordinated nanospheres (Pt@Ni-PCS); and re-dispersing the Pt@Ni-PCS in PBS, and sequentially adding a BALP antibody (Ab 2) and a BSA solution to obtain the Ab2-Pt@Ni-PCS quenching probe.
The invention provides a method for detecting bone-derived alkaline phosphatase, which comprises the following steps: the electrochemiluminescence immunosensor is used as a working electrode to be connected with an electrochemiluminescence detector; taking Phosphate Buffer Solution (PBS) as a detection base solution, and adding a coreactant Triethylamine (TEA) into the PBS for detection; and detecting the intensity of the electrochemiluminescence signal generated by the BALP with different concentrations by an electrochemiluminescence method under the preset condition of the electrochemiluminescence detector.
Further, the electrochemiluminescence detector is an ultra-weak electrochemiluminescence detector.
Further, the preset conditions comprise a photomultiplier with a high voltage of 800V, an electrochemical workstation cyclic voltammetry scanning potential range of 0.2-0.8V and a scanning rate of 0.2V/s.
Compared with the traditional luminescent material, the luminescent carbon nanomaterial prepared by the invention has smaller biotoxicity and excellent luminescent property of Zr-CD DRs; the synthesis method of the zirconium oxygen cluster coordination enrichment CDs ensures that CDs are more stable, ECL quantum efficiency is obviously improved, and ECL signals of the CDs are further improved.
The electrochemical luminescence immunosensor prepared by the invention adopts nickel-phenol coordination nanospheres (Ni-PCS) in the synthesis process, and a large number of active sites are provided for in-situ synthesis of platinum nanoparticles due to the large specific surface area of the Ni-PCS, so that antibodies (Ab 2) are further immobilized; and the Ni-PCS has a remarkable quenching effect on a Zr-CD DRs/TEA system, so that the detection sensitivity of the sensor is improved.
Further, the electrochemical luminescence immunosensor prepared by taking Zr-CD DRs as a luminescent material and Pt@Ni-PCS as a quenching material has excellent sensitivity, specificity, stability and clinical practicability when detecting bone-derived alkaline phosphatase, and the linear range is 1 pg/mL-50 ng/mL, and the detection limit is 24.9fg/mL.
Drawings
FIG. 1 is a schematic diagram of detection of BALP in an embodiment of the present invention, wherein FIG. 1A is the preparation of Zr-CD DRs and FIG. 1B is the preparation of Ab2-Pt@Ni-PCS quenching probe;
FIG. 2 is a topographical image of Zr-CD DRs in example 1 of the present invention, wherein FIG. 2A is a scanning electron microscope image of Zr-CD DRs, and comprises a partially magnified scanning electron microscope image of Zr-CD DRs (scale bar 500 nm); FIG. 2B is a transmission electron microscope image of Zr-CD DRs;
FIG. 3 is a morphology image of Ni-PCS and Pt@Ni-PCS in example 2 of the present invention, wherein FIG. 3A is a transmission electron microscope image of Ni-PCS, FIG. 3B is a transmission electron microscope image of Pt@Ni-PCS, and FIG. 3C is a partially enlarged Pt@Ni-PCS transmission electron microscope image;
FIG. 4 is a graph showing the construction process of the BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor of example 2, wherein FIG. 4A is an ECL intensity versus time curve and FIG. 4B is an electrochemical impedance curve;
FIG. 5 shows the viability of MDA-MB-468 cells after 48 hours incubation with CDs and Zr-CD DRs at different concentrations;
FIG. 6 is a calibration curve of ECL strength versus current for the material of example 1, wherein FIG. 6A is a calibration curve of ECL strength versus current for CDs; FIG. 6B is a calibration curve of ECL intensity versus current for Zr-CD DRs;
FIG. 7 is a graph showing the relationship between ECL intensity and BALP concentration of the electrochemical luminescence immunosensor for detecting BALP in example 2. Wherein, FIG. 7A is an electrochemiluminescence intensity versus time curve for detecting different concentrations of BALP using an electrochemiluminescence immunosensor; FIG. 7B is a plot of ECL intensity versus log BALP concentration for an electrochemiluminescence immunosensor, BALP concentration: a=1 pg/mL, b=10 pg/mL, c=100 pg/mL, d=1 ng/mL, e=10 ng/mL, f=50 ng/mL;
FIG. 8 shows ECL intensities for different non-target proteins for the electrochemiluminescence immunosensor for detecting BALP of example 2;
FIG. 9 is a graph of electrochemiluminescence signals of 10 consecutive cycles of the electrochemiluminescence immunosensor for detecting BALP of example 2 when detecting 10pg/mL and 10ng/mL BALP.
Detailed Description
For a better understanding of the nature of the present invention, reference should be made to the following description of the invention taken in conjunction with the accompanying drawings.
The luminescent carbon nanomaterial provided by the invention is prepared by the following method: preparing nitrogen-doped carbon dots; and carrying out coordination aggregation on the prepared nitrogen-doped carbon dots and zirconium oxygen clusters to obtain zirconium-coordinated carbon dot dendritic macromolecules (Zr-CD DRs), namely the luminescent carbon nanomaterial. The morphology structure of the Zr-CD DRs is shown in figure 2.
In the present invention, coordination-induced carbon dot aggregation is achieved by coordination between zirconium ions and carboxyl groups abundant on the surface of the carbon dot. The zirconium-coordinated carbon dot dendritic macromolecules (Zr-CD DRs) are formed by aggregation through coordination action between zirconium oxygen clusters and carboxyl groups of carbon dots, so that efficient and stable enrichment of the carbon dots can be realized. The zirconium oxygen clusters in Zr-CD DRs act as a barrier tape compared to the dispersed carbon dots such that a reasonable distance is maintained between the individual carbon dots to inhibit their aggregation quenching effect, thereby generating a strong and stable ECL signal such that ECL efficiency is significantly improved.
Wherein, the nitrogen-doped carbon point takes citric acid and hydrazine hydrate as raw materials, and is synthesized by adopting a solvothermal method.
The invention provides an electrochemiluminescence immunosensor, which comprises an immunosensor containing Zr-CD DRs and nickel phenol coordination nanospheres (Ni-PCS); the Zr-CD DRs are ECL signal labels and electrode modification materials, and the Ni-PCS is a signal quenching material, so that the high-sensitivity electrochemiluminescence immunosensor is formed, and the high-sensitivity electrochemiluminescence immunosensor is shown in figure 1.
Specifically, the immunosensor is prepared by sequentially assembling Zr-CD DRs and silver nano particles (AgNPs) on the surface of an electrode by taking the Zr-CD DRs as a substrate material, and then sequentially adopting a BALP antibody (Ab 1) and BSA to modify and construct the BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor. In some examples of the present invention, chitosan (CS) was used as a film former to immobilize Zr-CD DRs on the electrode surface and adsorb AgNPs with good conductivity, thereby immobilizing antibodies.
As shown in FIG. 3, the invention adopts nickel phenol coordination nanospheres (Ni-PCS) with larger specific surface area, takes the nickel phenol coordination nanospheres as a carrier of platinum nanoparticles, takes the platinum nanoparticles as active sites to immobilize antibodies, and meanwhile, the Ni-PCS has high-efficiency quenching effect on Zr-CD DRs/TEA systems, thereby realizing high-sensitivity detection of an immunosensor.
When the electrochemical luminescence immunosensor is used for detecting BALP, the electrochemical luminescence immunosensor modified by Zr-CD DRs can obtain a stronger ECL signal under the assistance of Triethylamine (TEA) serving as a coreactant. Ab2-Pt@Ni-PCS quenching probe is introduced to the modified electrode interface by using sandwich immune reaction in the presence of BALP. Due to the quenching effect of Pt@Ni-PCS on the Zr-CD DRs/TEA system, a low ECL signal was obtained. With increasing BALP concentration, ECL signal gradually decreases, thereby realizing highly sensitive detection of BALP.
Example 1
1. A luminescent carbon nanomaterial is prepared by the following steps:
(1) And preparing nitrogen-doped carbon dots.
2.1g of citric acid was dissolved in 10mL of N, N-Dimethylformamide (DMF), then 1.0mL of hydrazine hydrate was added dropwise to the above solution under stirring, and the above mixture was transferred to a stainless steel autoclave lined with polytetrafluoroethylene for solvothermal reaction. After the reaction was heated in an oven at 180℃for 12 hours, it was cooled to room temperature, and then the resulting brownish black solution was centrifuged (12000 rpm,10 minutes) to remove large particle residues. After dialysis of the centrifuged upper solution in deionized water for 48 hours, it was dried at 60℃and the resulting nitrogen-doped Carbon Dots (CDs) powder was stored in a closed brown container and placed at 4℃for further use.
(2) Zirconium coordinated carbon dot dendrimer materials (Zr-CD DRs) were prepared.
ZrOCl 2 ·8H 2 O (30 mg) was dissolved in 10mL of DMF (1 mg/mL) containing the above synthesized nitrogen-doped Carbon Dots (CDs). The mixture was heated in an oil bath at 90 ℃ for 5 hours and then cooled naturally to room temperature. The product was then washed by centrifugation to give Zr-CD DRs. Finally, the Zr-CD DRs precipitate was dried at 60℃and stored at 4℃for further use.
To confirm successful synthesis of Zr-CD DRs, the morphology was characterized by scanning electron microscopy. As shown in FIG. 2A, the morphology of Zr-CD DRs is an irregular multi-layer coral-like structure. In addition, the morphology of the prepared Zr-CD DRs was also characterized by transmission electron microscopy (FIG. 2B). The transmission electron microscope image showed a multi-layered coral structure, similar to the scanning electron microscope image.
2. The Zr-CD DRs prepared above were subjected to a biotoxicity test.
Biocompatibility is an important parameter in evaluating whether a biological material is suitable for use in biomedical applications. In order to evaluate the feasibility of CDs and Zr-CD DRs as good biomedical materials, the present invention adopts CCK-8 experiment to detect cytotoxicity of CDs and Zr-CD DRs prepared in step (2) on human breast cancer cells (MDA-MB-468) cultured in vitro, and the results are shown in FIG. 5. As can be seen from the results of FIG. 5, the cell viability of Zr-CD DRs was significantly higher than that of dispersed CDs in the cell samples of the different concentration groups (10, 50, 100 and 500. Mu.g/mL). In addition, after 48 hours incubation with Zr-CD DRs, the cell viability was about 75%, which was higher than that of the gold nanoparticle group of 1.0. Mu.g/mL, indicating lower cytotoxicity.
3. ECL quantum efficiency of Zr-CD DRs prepared as described above was verified.
The electrochemiluminescence quantum efficiency is an important parameter for quantifying ECL performance, and ECL intensity is proportional to faraday current in an electrochemiluminescence system. The relative ECL quantum efficiency of Zr-CD DRs and CDs is obtained through calculation.
The quantitative relationship between ECL intensity and current of CDs and Zr-CD DRs systems is obtained by the formula (1) and the formula (2):
I CDs ＝k CDs i F ＝2060.12i+3865.78 (1)
wherein I is CDs ECL intensity, k for CDs CDs Slope of linear response curve for CDs, i F Is Faraday current.
I Zr-CD DRs ＝k Zr-CD DRs i F ＝4241.51i+2983.87 (2)
Wherein I is Zr-CD DRs Is ZECL intensity, k of r-CD DRs Zr-CD DRs Is the slope of the linear response curve of Zr-CDDRs.
The relative ECL quantum efficiency ratio (Q) of Zr-CD DRs to CDs can be obtained from equation (3):
wherein,ECL quantum efficiency for Zr-CD DRs, < >>ECL quantum efficiency as CDs.
As can be obtained from the formulas (1) to (3),
the results show that the ECL quantum efficiency of Zr-CD DRs is improved by 2.1 times compared with CDs, which indicates that zirconium oxygen clusters aggregate CDs through coordination interaction to be an effective way for improving the ECL quantum efficiency.
Example 2
1. The preparation of the secondary anti-platinum nano functionalized nickel phenol nanosphere (Ab 2-Pt@Ni-PCS) quenching probe comprises the following preparation steps:
(1) Preparation of Ni-PCS
Synthesizing nickel phenol coordination nanospheres (Ni-PCS) by formaldehyde-assisted metal ligand crosslinking method. The method comprises the following specific steps: (i) 0.1g Pluronic F127 was dissolved in a mixed solution of 4mL ethanol and 23mL deionized water. (ii) 0.25mL of an aqueous ammonia solution (25 wt%) was added dropwise to the mixed solution, and after stirring for 1 hour, 0.1g of tannic acid was added. (iii) After complete dissolution of the tannic acid, 0.19mL of formaldehyde solution (37 wt%) was added and stirring was continued for 24 hours. (iv) NiCl is added 2 Solution (0.05 g NiCl) 2 Dissolved in 1mL of deionized water) was added to the above mixture solution and stirring was continued for 24 hours. (v) Transferring the mixed solution into a high-pressure reaction kettle, and performing hydrothermal treatment in a 100 ℃ oven for 24 hours. (vi) The resulting product (Ni-PCS) was centrifuged and washed (12000 rpm,10 minutes) and then redispersed in deionized water and placed at 4℃for further use. The Ni-PCS had a uniform spherical shape with a diameter of about 500nm and a rough surface, as shown in FIG. 3A.
(2) Preparation of Pt@Ni-PCS
After Ni-PCS was obtained, synthesis of platinum nanoparticle functionalized nickel phenolic coordination spheres (Pt@Ni-PCS) continued. The method comprises the following specific steps: (i) 0.5mL of the prepared Ni-PCS solution was dispersed in 1.5mL of deionized water containing 25mg of polyvinylpyrrolidone (PVP). (ii) After stirring for 30 minutes, 2.4mL H was added 2 PtCl 6 (0.3 mM) and stirring was continued for 10 minutes. (iii) Then 0.125mL NaBH 4 (3 mM) was added dropwise to the above solution, and reacted for 30 minutes. (iv) The mixed solution was centrifuged (12000 rpm,10 minutes) and washed 3 times with ethanol. (v) The resulting final product Pt@Ni-PCS was redispersed in deionized water and stored at 4℃for further use.
As shown in FIGS. 3B and 3C, platinum nanoparticles with a diameter of about 5nm were uniformly distributed on the surface of the sphere, indicating that Pt@Ni-PCS was successfully synthesized.
(3) Preparation of Ab2-Pt@Ni-PCS
100. Mu.L of BALP antibody (Ab 2, 10. Mu.g/mL) was added dropwise to 1mL of the Pt@Ni-PCS solution prepared above, followed by stirring at 4℃for 12 hours, followed by blocking the non-specific adsorption sites with BSA solution (0.5 wt%), and finally the prepared Ab2-Pt@Ni-PCS quenching probe was stored at 4℃for further use.
2. Preparation of BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor
(1) 3.4mg AgNO 3 Dissolved in 20mL deionized water cooled to about 10 ℃. Subsequently, 4.53mg NaBH 4 And 24mg sodium citrate were added to the AgNO 3 The solution was stirred in an ice bath for 30 minutes. Finally, the prepared AgNPs solution was stored in a brown closed container and placed in storage at 4 ℃ for further use.
(2) Polishing a Glassy Carbon Electrode (GCE) with the diameter of 4mm to a mirror surface by using alumina powder with the diameter of 0.05 mu m, and then washing the mirror surface by using deionized water; zr-CD DRs were dispersed in a 0.1wt% Chitosan (CS) solution and added dropwise to the pretreated GCE surface after complete dispersion. After naturally airing, obtaining the stable Zr-CD DRs/CS film. Subsequently 10. Mu.L of AgNPs solution was dropped on the Zr-CD DRs/CS modified GCE surface and incubated for 4 hours at room temperature. Then 10. Mu.L of 10. Mu.g/mL BALP antibody (Ab 1) was added dropwise to the modified electrode surface and reacted at 4℃for 8 hours. Finally, 10. Mu.L of BSA (0.25 wt%) solution was dropped onto the modified electrode, and the non-specific adsorption sites were blocked by incubation at 4℃for 40 minutes, to prepare a BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor.
(3) Electrochemiluminescence and electrochemical impedance characterization of the immunosensor prepared in step (2).
To verify the electrode modification procedure, ECL characterization was performed on electrodes of varying degrees of modification in PBS containing coreactant TEA, as shown in FIG. 4A, where a is bare GCE, b is Zr-CD DRs/CS/GCE, c is AgNPs/Zr-CD DRs/CS/GCE, d is Ab1/AgNPs/Zr-CD DRs/CS/GCE, e is BSA/Ab1/AgNPs/Zr-CD DRs/CS/GCE, f is BALP/BSA/Ab1/AgNPs/Zr-CD DRs/CS/GCE, g is Ab 2-Pt@Ni-BALP/BSA/1/AgNPs/Zr-CD DRs/CS/GCE.
Bare GCE electrodes exhibit almost negligible ECL signals (curve a). The Zr-CD DRs/CS film is modified on the surface of the electrode, and a stronger ECL signal (curve b) is obtained. After subsequent incubation of the AgNPs on the modified electrodes described above, the ECL signal was further enhanced (curve c) due to the good conductivity of the AgNPs. ECL signal was sequentially attenuated with continued incubation of Ab1, BSA and target BALP at the modified electrode surface (d-f curve). This continuous ECL signal attenuation is due to the fact that the above materials are all non-electroactive materials that hinder electron transfer. After introduction of the Ab2-Pt@Ni-PCS quenching probe by sandwich immune reaction, ECL signal was significantly reduced (curve g) because Ni-PCS was able to effectively quench ECL signal of Zr-CD DRs/TEA system. The ECL signal changes described above indicate successful construction of immunosensors.
To further evaluate whether the electrochemical luminescence immunosensor was successful, the present invention was performed in 5mM [ Fe (CN) with 0.1M KCl 6 ] 3-/4- Electrochemical impedance characterization was performed in the system. As shown in fig. 4B, the diameter of the semicircle represents the electron transfer resistance (Ret). Bare GCE presentation due to free electron transferA smaller semicircular area (curve a) is shown. After modification of Zr-CD DRs/CS on GCE, a larger semicircular region was observed (curve b), indicating that less conductive chitosan impeded electron transfer. Since AgNPs have good conductivity, after adsorption of AgNPs on the chitosan surface, the semicircular area (curve c) is reduced compared to curve b. After sequential modification of the electrode with Ab1, BSA, BALP and Pt@Ni-PCS-Ab2 quenching probes, the resistance increases in turn (curve d-g) due to the inhibitory effect of the protein as an inert electron layer.
In summary, the electrochemical luminescence and the electrochemical impedance characterization show successful preparation of immunosensors.
3. The preparation of the electrochemiluminescence immunosensor for detecting BALP comprises the following steps:
(1) A series of BALP standard solutions (10 mu L) with different concentrations are dripped on the surface of a BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor and reacted for 1 hour, and then the electrode interface is washed by PBS (pH 7.4);
(2) And (3) dripping 10 mu L of the prepared Ab2-Pt@Ni-PCS quenching probe onto the surface of an electrode, placing the electrode at the temperature of 4 ℃ for reaction for 1 hour, and then flushing the electrode with PBS (pH 7.4) to obtain the electrochemiluminescence immunosensor for detecting BALP.
4. The detection performance of the electrochemiluminescence immunosensor prepared as described above was analyzed, and the results are shown in fig. 7. Wherein, FIG. 7A shows that the concentration of the target BALP is in the range of 1 pg/mL-50 ng/mL, and the response ECL signal of the electrochemiluminescence immunosensor prepared by the invention gradually decreases along with the increase of the concentration of the target BALP. While the corresponding calibration curve (fig. 7B) shows that ECL signal is logarithmically related to the concentration of BALP, its linear equation is i= -1122.75lg c+7385.0, where I is ECL intensity, c is target BALP concentration, correlation coefficient (R 2 ) 0.9979. Thus, the detection Limit (LOD) of the electrochemiluminescence immunosensor prepared in the invention is 24.9fg/mL through calculation. In conclusion, the electrochemiluminescence immunosensor prepared by the invention has excellent sensitivity in detecting bone-derived alkaline phosphatase.
5. The specificity and stability of the electrochemiluminescence immunosensor prepared as described above were evaluated.
Alpha Fetoprotein (AFP), laminin (LN), prostate Specific Antigen (PSA) and Human Serum Albumin (HSA) were selected as interfering proteins for detection. As a result, as shown in FIG. 8, the concentrations of AFP, LN, PSA and HAS were 10ng/mL.
As can be seen from FIG. 8, the ECL intensity of the interfering protein remained at a high level, with no significant difference from the blank, despite the concentration of the interfering protein as high as 10ng/mL. Whereas at a BALP concentration of 1ng/mL, ECL intensity was significantly reduced. In addition, the ECL strength of the mixture containing 1ng/mL BALP and 10ng/mL interfering protein (AFP, LN, PSA and HSA) was similar to that of 1ng/mL BALP alone. The results show that the electrochemiluminescence immunosensor prepared by the invention has excellent specificity.
FIG. 9 shows that the immunosensor prepared by the invention continuously scans ECL signals for 10 cycles when detecting 10pg/mL and 10ng/mL BALP, wherein ECL intensity is relatively stable, RSD is 2.52% and 0.92% respectively, and the electrochemical luminescence immunosensor prepared by the invention has good stability.
Example 3
The electrochemiluminescence immunosensor prepared in example 2 was used to detect BALP as follows:
(1) Parameter setting: the high voltage of a photomultiplier of the ultra-weak electrochemiluminescence instrument is set to 800V, the cyclic voltammetry scanning potential range of an electrochemical workstation is set to 0.2-0.8V, and the scanning rate is set to 0.2V/s;
(2) An Ag/AgCl electrode is used as a reference electrode, a platinum wire electrode is used as a counter electrode, the prepared electrochemical luminescence sensor is used as a working electrode, and the working electrode is connected in a cassette of an electrochemical luminescence detector, so that an electrochemical workstation and the electrochemical luminescence detector are connected together;
(3) Detection was performed in 2mL of 0.1mol/L PBS (pH 8.0) containing 35mmol/L of coreactant TEA, and the intensity of the electrochemiluminescence signal generated by the different concentrations of BALP was detected by electrochemiluminescence;
(4) And drawing a working curve according to the linear relation between the obtained electrochemiluminescence intensity value and the BALP concentration logarithm.
Example 4
The electrochemiluminescence immunosensor prepared in example 2 was used to detect bone-derived alkaline phosphatase (BALP) in serum by standard addition method, and bone-derived alkaline phosphatase with different concentrations was added to diluted serum, and the average recovery rate of bone-derived alkaline phosphatase in the sample was determined, and the results are shown in Table 1.
TABLE 1 Standard addition method for detecting bone derived alkaline phosphatase in serum samples.
The detection results in table 1 show that the recovery rate of the bone source alkaline phosphatase detection results in the sample is 95.7% -101.3%, which indicates that the electrochemiluminescence immunosensor can be applied to detection of actual biological samples, and the results are accurate and reliable.
The foregoing is illustrative of the present invention and is not to be construed as limiting thereof, but rather as providing for the use of additional embodiments and advantages of all such modifications, equivalents, improvements and similar to the present invention are intended to be included within the scope of the present invention as defined by the appended claims.
Claims (10)
1. The preparation method of the luminescent carbon nanomaterial is characterized by comprising the following steps of: mixing a raw material for preparing nitrogen-doped carbon dots with Dimethylformamide (DMF) to form DMF containing the nitrogen-doped carbon dots; and carrying out coordination aggregation on the DMF containing the nitrogen-doped carbon dots and the zirconium oxygen clusters to obtain zirconium coordinated carbon dot dendritic macromolecules (Zr-CD DRs), namely the luminescent carbon nanomaterial.
2. The method of manufacture of claim 1, wherein: the nitrogen-doped carbon point is synthesized by taking citric acid and hydrazine hydrate as raw materials and adopting a solvothermal method; the solvothermal method for synthesizing the nitrogen-doped carbon dot specifically comprises the following steps of:
dissolving citric acid in Dimethylformamide (DMF), and then adding hydrazine hydrate dropwise to the DMF solution under stirring to form a mixture;
transferring the mixture into a high-pressure reaction kettle with polytetrafluoroethylene lining for solvothermal reaction, cooling to room temperature after the reaction is completed, and centrifuging to obtain an upper solution.
3. The preparation method according to claim 1, wherein the coordination aggregation of the nitrogen-doped carbon dots and zirconium oxygen clusters specifically comprises the following steps:
ZrOCl 2 ·8H 2 O is dissolved in DMF containing nitrogen-doped carbon dots, and is obtained by heating and cooling to room temperature and then separating.
4. A luminescent carbon nanomaterial characterized in that it is prepared by the method of claim 2.
5. An electrochemiluminescence immunosensor, characterized in that: comprises an immunosensor containing Zr-CD DRs and a probe containing nickel-phenol coordination nanospheres (Ni-PCS); the Zr-CD DRs are electrochemical luminescence signal labels and electrode modification materials, and the Ni-PCS is a signal quenching material; the Zr-CD DRs are luminescent carbon nanomaterial of claim 4; the immunosensor containing Zr-CD DRs is a BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor; the probe of the nickel-phenol-containing coordination nanosphere (Ni-PCS) is an Ab2-Pt@Ni-PCS quenching probe.
6. The electrochemiluminescence immunosensor of claim 5, wherein: the BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor is prepared by the following steps:
s1, dispersing Zr-CD DRs in a chitosan solution, and then dropwise adding the dispersed Zr-CD DRs onto the surface of a pretreated glassy carbon electrode to obtain a Zr-CD DRs/CS modified electrode;
s2, silver nano particles (AgNPs) solution is dripped on the surface of the Zr-CD DRs/CS modified electrode, and the AgNPs/Zr-CD DRs/CS modified electrode is obtained;
s3, dripping the BALP antibody (Ab 1) to the surface of the AgNPs/Zr-CDDRs/CS modified electrode obtained in the step S2 to obtain an Ab1/AgNPs/Zr-CD DRs/CS modified electrode;
s4, dropwise adding a blocking agent BSA solution to the surface of the electrode modified by the Ab1/AgNPs/Zr-CDDRs/CS obtained in the step S3 to obtain the BSA/Ab1/AgNPs/Zr-CD DRs/CS immunosensor.
7. The electrochemiluminescence immunosensor of claim 5, wherein the Ab2-pt@ni-PCS quenching probe is prepared by:
synthesizing Ni-PCS by formaldehyde auxiliary metal ligand crosslinking method;
dispersing the Ni-PCS solution in deionized water containing polyvinylpyrrolidone (PVP), mixing, adding H 2 PtCl 6 The solution is slightly stirred and then added with a reducing agent NaBH 4 The reaction and separation are carried out to obtain platinum nanoparticle functionalized nickel phenol coordination nanospheres (Pt@Ni-PCS); and re-dispersing the Pt@Ni-PCS in PBS, and sequentially adding a BALP antibody (Ab 2) and a BSA solution to obtain the Ab2-Pt@Ni-PCS quenching probe.
8. A method for detecting bone-derived alkaline phosphatase, comprising the steps of:
connecting the electrochemiluminescence immunosensor of any one of claims 5 to 7 as a working electrode to an electrochemiluminescence detector;
taking Phosphate Buffer Solution (PBS) as a detection base solution, and adding a coreactant Triethylamine (TEA) into the PBS for detection;
and detecting the intensity of the electrochemiluminescence signal generated by the BALP with different concentrations by an electrochemiluminescence method under the preset condition of the electrochemiluminescence detector.
9. The method for detecting bone-derived alkaline phosphatase according to claim 8, wherein: the electrochemiluminescence detector is an ultra-weak electrochemiluminescence detector.
10. The method for detecting bone-derived alkaline phosphatase according to claim 8, wherein: the preset conditions comprise that the high voltage of the photomultiplier is 800V, the cyclic voltammetry scanning potential range of the electrochemical workstation is 0.2-0.8V, and the scanning rate is 0.2V/s.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211406375.9A CN115873596B (en) | 2022-11-10 | 2022-11-10 | Luminescent carbon nanomaterial and application thereof in bone-derived alkaline phosphatase detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211406375.9A CN115873596B (en) | 2022-11-10 | 2022-11-10 | Luminescent carbon nanomaterial and application thereof in bone-derived alkaline phosphatase detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115873596A CN115873596A (en) | 2023-03-31 |
| CN115873596B true CN115873596B (en) | 2023-11-17 |
Family
ID=85759655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211406375.9A Active CN115873596B (en) | 2022-11-10 | 2022-11-10 | Luminescent carbon nanomaterial and application thereof in bone-derived alkaline phosphatase detection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115873596B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001031A (en) * | 2014-10-14 | 2017-08-01 | 芝加哥大学 | Nano particle for photodynamic therapy, the photodynamic therapy of X ray induction, radiotherapy, chemotherapy, immunotherapy and its any combination |
| CN110987843A (en) * | 2019-11-19 | 2020-04-10 | 江苏大学 | Phosphate radical colorimetric detection method based on bimetallic MOF nano-oxidase |
| CN112210365A (en) * | 2019-07-11 | 2021-01-12 | 天津大学 | Method for preparing nano zirconium dioxide carbon quantum dot composite material by one-pot method |
| CN113429960A (en) * | 2021-07-05 | 2021-09-24 | 四川师范大学 | Can be used for trace Cu2+Carbon quantum dot composite UiO-66 derivative for ion detection |
| CN113441113A (en) * | 2021-07-14 | 2021-09-28 | 武汉市第三医院 | Carbon nano-dot functionalized zirconium-based metal organic framework compound composite material and preparation method thereof |
| CN114106825A (en) * | 2021-12-17 | 2022-03-01 | 陕西工业职业技术学院 | Sulfur-phosphorus co-doped carbon point @ Zr-MOFs based on sesame straw and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012129150A2 (en) * | 2011-03-18 | 2012-09-27 | University Of Maryland, Baltimore County | Metal-enhanced photoluminescence from carbon nanodots |
| US10806694B2 (en) * | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
| WO2020162538A1 (en) * | 2019-02-08 | 2020-08-13 | 旭化成株式会社 | Sensor |
-
2022
- 2022-11-10 CN CN202211406375.9A patent/CN115873596B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001031A (en) * | 2014-10-14 | 2017-08-01 | 芝加哥大学 | Nano particle for photodynamic therapy, the photodynamic therapy of X ray induction, radiotherapy, chemotherapy, immunotherapy and its any combination |
| CN112210365A (en) * | 2019-07-11 | 2021-01-12 | 天津大学 | Method for preparing nano zirconium dioxide carbon quantum dot composite material by one-pot method |
| CN110987843A (en) * | 2019-11-19 | 2020-04-10 | 江苏大学 | Phosphate radical colorimetric detection method based on bimetallic MOF nano-oxidase |
| CN113429960A (en) * | 2021-07-05 | 2021-09-24 | 四川师范大学 | Can be used for trace Cu2+Carbon quantum dot composite UiO-66 derivative for ion detection |
| CN113441113A (en) * | 2021-07-14 | 2021-09-28 | 武汉市第三医院 | Carbon nano-dot functionalized zirconium-based metal organic framework compound composite material and preparation method thereof |
| CN114106825A (en) * | 2021-12-17 | 2022-03-01 | 陕西工业职业技术学院 | Sulfur-phosphorus co-doped carbon point @ Zr-MOFs based on sesame straw and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Quick and hassle‑free smartphone’s RGB‑based color to photocatalytic degradation rate assessment of malachite green dye in water by fluorescent Zr–N–S co‑doped carbon dots;Harshita Laddha等;《Environmental Science and Pollution Research》;第29卷;第56684–56695页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115873596A (en) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qin et al. | A novel carbon quantum dots signal amplification strategy coupled with sandwich electrochemiluminescence immunosensor for the detection of CA15-3 in human serum | |
| Vidotti et al. | Biosensors based on gold nanostructures | |
| Pothipor et al. | Highly sensitive biosensor based on graphene–poly (3-aminobenzoic acid) modified electrodes and porous-hollowed-silver-gold nanoparticle labelling for prostate cancer detection | |
| Pavithra et al. | Development of novel paper based electrochemical immunosensor with self-made gold nanoparticle ink and quinone derivate for highly sensitive carcinoembryonic antigen | |
| Li et al. | An ultrasensitive electrochemical immunosensor for CEA using MWCNT-NH 2 supported PdPt nanocages as labels for signal amplification | |
| Khalilzadeh et al. | Ultrasensitive caspase-3 activity detection using an electrochemical biosensor engineered by gold nanoparticle functionalized MCM-41: Its application during stem cell differentiation | |
| Liu et al. | Electrochemical immunosensor for salbutamol detection based on CS-Fe3O4-PAMAM-GNPs nanocomposites and HRP-MWCNTs-Ab bioconjugates for signal amplification | |
| Ma et al. | Ultrasensitive immunosensor for prostate-specific antigen based on enhanced electrochemiluminescence by vertically ordered mesoporous silica-nanochannel film | |
| Zhang et al. | Gold–silver nanocomposite-functionalized graphene sensing platform for an electrochemiluminescent immunoassay of a tumor marker | |
| Putnin et al. | Dually functional polyethylenimine-coated gold nanoparticles: a versatile material for electrode modification and highly sensitive simultaneous determination of four tumor markers | |
| CN112391347B (en) | Magneto-optical composite nanostructures, methods of making the same, and methods of detecting, separating, or imaging analytes | |
| Zhou et al. | Water-soluble pillar [6] arene functionalized PdPt porous core-shell octahedral nanodendrites to construct highly sensitive and robust neuron-specific enolase immunosensor by host-guest chemistry assisted catalytic amplification | |
| Li et al. | Multi-amplification of the signal of voltammetric immunosensors: Highly sensitive detection of tumor marker | |
| Li et al. | An electrochemiluminescent biosensor for noninvasive glucose detection based on cluster-like AuAg hollowed-nanoparticles | |
| Valverde et al. | Carbon/Inorganic Hybrid Nanoarchitectures as Carriers for Signaling Elements in Electrochemical Immunosensors: First Biosensor for the Determination of the Inflammatory and Metastatic Processes Biomarker RANK‐ligand | |
| Lai et al. | Electrochemiluminescence immunosensors based on ECL-RET triggering between Mn SANE/PEI-luminol and PtCu/h-MPF for ultrasensitive detection of CEA | |
| Liu et al. | Nanovehicles based bioassay labels | |
| CN109813786A (en) | Bimetallic-organic framework material, timbering material and preparation method thereof, electrochemical immunosensor and preparation method thereof, application | |
| CN113155930A (en) | Electrochemical immunosensing method for detecting leukemia stem cell tumor marker CD123 by using multiple signal amplification technology | |
| Lu et al. | Detection of squamous cell carcinoma antigen in cervical cancer by surface-enhanced Raman scattering-based immunoassay | |
| Patel et al. | Signal amplification strategies in electrochemical biosensors via antibody immobilization and nanomaterial-based transducers | |
| Jiang et al. | An optionality further amplification of an sandwich-type electrochemical immunosensor based on biotin–streptavidin–biotin strategy for detection of alpha fetoprotein | |
| Sajadpour et al. | Label-free PSA electrochemical determination by seed-mediated electrochemically-deposited gold nanoparticles on an FTO electrode | |
| Chang et al. | Novel dual‐sensitization electrochemiluminescence immunosensor using photopermeable Ru (bpy) 32+‐doped chitosan/SiO2 nanoparticles as labels and chitosan‐decorated Nafion/MWNTs composites as enhancer | |
| Lv et al. | Self-supported PtPdMnCoFe high-entropy alloy with nanochain-like internetworks for ultrasensitive electrochemical immunoassay of biomarker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |